Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 1/20 | 0.53 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.53 |
| ▸ | KYNU | Q16719 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30573232 | 1.00 | CPN1 (0.53) | CPN1CPB2KYNUKDM4EALDH1A1 | |
| SCHEMBL1104877 | 1.00 | CPN1 (0.53) | CPN1CPB2KYNUKDM4EALDH1A1 | |
| SCHEMBL1366777 | 1.00 | CPN1 (0.53) | CPN1CPB2KYNUKDM4EALDH1A1 | |
| SCHEMBL758770 | 0.82 | CPN1 (0.53) | CPN1CPB2KYNUALDH1A1L3MBTL1 | |
| SCHEMBL2190991 | 0.81 | CPN1 (0.44) | CPN1CPB2KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL5038096 | 0.81 | KYNU (0.55) | KYNUKDM4EALDH1A1CYP3A4PPARA | |
| SCHEMBL6611635 | 0.81 | ACP3 (0.47) | KDM4EL3MBTL1PPARALMNA | |
| SCHEMBL14159225 | 0.79 | ALDH1A1 (0.49) | KDM4EALDH1A1L3MBTL1KMT2APPARA | |
| SCHEMBL1145682 | 0.79 | L3MBTL1 (0.56) | L3MBTL1LMNA | |
| SCHEMBL18890289 | 0.79 | L3MBTL1 (0.56) | L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12291494-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2025-05-06 | — | — | US | disclosed |
| US-20240279157-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2024-08-22 | — | — | US | disclosed |
| US-11753365-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2023-09-12 | — | — | US | disclosed |
| CN-116602950-A | Methods of treating fibrosis | 诺格拉制药有限公司 | 2023-08-18 | — | — | CN | disclosed |
| US-20220033346-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2022-02-03 | — | — | US | disclosed |
| US-11046641-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2021-06-29 | — | — | US | disclosed |
| US-20210113505-A1 | METHODS OF TREATING HAIR RELATED CONDITIONS | NOGRA PHARMA LTD (IE) | 2021-04-22 | — | — | US | disclosed |
| EP-3628317-A1 | METHODS OF TREATING FIBROSIS | Nogra Pharma Limited (IE) | 2020-04-01 | — | — | EP | disclosed |
| EP-2811993-B1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LTD (IE) | 2019-10-09 | — | — | EP | disclosed |
| EP-2895160-B1 | METHODS OF TREATING HAIR RELATED CONDITIONS | NOGRA PHARMA LTD (IE) | 2018-05-30 | — | — | EP | disclosed |
| WO-2013156413-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LIMITED (IE) | 2013-10-24 | — | — | WO | disclosed |
| WO-2013117744-A9 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013117744-A2 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2013-08-15 | — | — | WO | disclosed |
| US-8501806-B2 | Methods for preventing or reducing colon carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2013-08-06 | — | — | US | disclosed |
| US-20110288058-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2011-11-24 | — | — | US | disclosed |
| US-20110288177-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2011-11-24 | — | — | US | disclosed |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | NOGRA PHARMA LIMITED (IE) | 2011-06-23 | — | — | US | disclosed |
| EP-2131829-A1 | PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS | Giuliani International Limited (IE) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008104557-A1 | PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS | GIULIANI INTERNATIONAL LIMITED (IE) | 2008-09-04 | — | — | WO | disclosed |
| US-5707991-A | TREATMENT OF NERVOUS SYSTEM DISORDERS, PARKINSON'S DISEASE | RHONE-POULENC RORER S.A. (FR) | 1998-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753365-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | CPN1 2301/4885CPB2 451/4885KYNU 3705/4885 |
| US-20110288058-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NQO1, NFE2L2, CYBB | CPN1 3258/4885CPB2 1102/4885KYNU 1817/4885 |
| US-20210113505-A1 | METHODS OF TREATING HAIR RELATED CONDITIONS | EBP, AADAT, ALDH7A1 | CPN1 2341/4885CPB2 2006/4885KYNU 274/4885 |
| US-20240279157-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | CPN1 2301/4885CPB2 451/4885KYNU 3705/4885 |
| US-20110288177-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | APC, GSTK1, GSTA1 | CPN1 3029/4885CPB2 1741/4885KYNU 3063/4885 |
| US-12291494-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | CPN1 2301/4885CPB2 451/4885KYNU 3705/4885 |
| US-11046641-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | CPN1 2301/4885CPB2 451/4885KYNU 3705/4885 |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | PPARG, FABP2, PPARD | CPN1 2091/4885CPB2 1744/4885KYNU 3961/4885 |
| US-20220033346-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | CPN1 2301/4885CPB2 451/4885KYNU 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.